Jeremy Curnock Cook on Sky News Business (The Perrett Report) Oct 27, 2015. Additionally it can be downloaded here: https://www.hightail.com/download/bXBZZUNxeFhRWUlsYzlVag
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-10-27 16:55:182018-01-06 16:55:53Jeremy Curnock Cook spoke to Sky News Business 27 Oct 2015
Australia, 20 October 2015 — ASX link here. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today the closing of a AUD$ 10,018,644 common stock placement to sophisticated and institutional investors through the issue of 107,727,358 shares at a price of AUD $0. […]
DUBLIN, Ireland, Oct. 19, 2015 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the initiation of a pilot field study for its product candidate NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) for the control of pain associated with osteoarthritis in cats. The initiation of this field study represents […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-10-19 16:56:562018-01-06 16:57:30Nexvet Initiates Pilot Field Study of NV-02 for Feline Osteoarthritis Pain
Avita Medical announcement link here. · POSITIVE RESULTS FROM INTERIM UPDATE ON 20-PATIENT, RANDOMIZED, CONTROLLED STUDY OF RESTORATION OF PIGMENT IN HYPOPIGMENTED BURN SCARS · CONTINUED POSITIVE DATA FROM REPIGMENTATION TRIALS TO FORM BASIS FOR PIII PIVOTAL IDE SUBMISSION WITH US FDA NORTHRIDGE, Calif., and CAMBRIDGE, United Kingdom, 18 October 2013– Regenerative medicine Company Avita Medical Ltd. (ASX: AVH), (OTCQX:AVMXY) is […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-10-18 16:56:042018-01-06 16:56:46Avita Medical Announces Positive Interim Clinical Study Results On Restoration of Pigment in Burn Scars at Clinical Cosmetic & Reconstructive Expo
October 14, 2015: 9NEWS spoke exclusively to the first patient to undergo the new treatment that is giving hope to sufferers of back pain. Read more at http://www.9news.com.au/national/2015/10/14/19/04/aussie-innovation-gives-hope-to-back-pain-sufferers#b0dfx4DwJTTVgPDM.99
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-10-14 16:58:422018-01-06 16:59:12Saluda Medical – Aussie innovation gives hope to back pain sufferers
Harriet Alexander Sydney Morning Herald. Published: October 14, 2015 6:34PM Every minute of the night and day, for decades, Jaswir Grewal was in pain. The constant ache in his back forced him to leave his jobs as a mechanic and banana grower. The pain troubled his sleep, made him irritable with his wife, depressed about his […]
Northridge, CA and Cambridge, United Kingdom, 7 October 2015 Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-10-07 16:59:582018-01-06 17:00:32Avita Medical Gains CE Mark for ReGenerCell® and ReNovaCell® to Complete Skin Healing Portfolio Certification Applies to ReCell®, ReGenerCell® and ReNovaCell®
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-10-05 17:02:232018-01-06 17:02:56Avita Medical CEO Adam Kelliher interviewed on CommSec
Northridge, CA and Cambridge, United Kingdom, 5 October 2015 Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced approval from the U.S. Food and Drug Administration (FDA) for the expansion of its Compassionate Use Investigational Device Exemption (IDE) program for ReCell®. The IDE […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-10-05 17:01:402018-01-06 17:02:14Avita Medical Announces U.S. FDA Doubles Patient Numbers Permitted for Compassionate Use of ReCell®
SEA: NZX and Media Release 30 September 2015. NZX link here. SeaDragon raises $10.009 million via rights offer and shortfall bookbuild, and additional placement Successful capital raising at $0.008 per share facilitates the completion of the company’s new Omega-3 fish oil refinery. New Zealand’s leading refiner and blender of high-quality fish oils SeaDragon Limited (NZX:SEA) today […]
Jeremy Curnock Cook spoke to Sky News Business 27 Oct 2015
/in BioSciences ManagersJeremy Curnock Cook on Sky News Business (The Perrett Report) Oct 27, 2015. Additionally it can be downloaded here: https://www.hightail.com/download/bXBZZUNxeFhRWUlsYzlVag
Avita Medical Announces AUD$ 10M Equity Financing
/in Avita Medical, Portfolio CompaniesAustralia, 20 October 2015 — ASX link here. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today the closing of a AUD$ 10,018,644 common stock placement to sophisticated and institutional investors through the issue of 107,727,358 shares at a price of AUD $0. […]
Nexvet Initiates Pilot Field Study of NV-02 for Feline Osteoarthritis Pain
/in Pharmamark, Portfolio CompaniesDUBLIN, Ireland, Oct. 19, 2015 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the initiation of a pilot field study for its product candidate NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) for the control of pain associated with osteoarthritis in cats. The initiation of this field study represents […]
Avita Medical Announces Positive Interim Clinical Study Results On Restoration of Pigment in Burn Scars at Clinical Cosmetic & Reconstructive Expo
/in Avita Medical, Portfolio CompaniesAvita Medical announcement link here. · POSITIVE RESULTS FROM INTERIM UPDATE ON 20-PATIENT, RANDOMIZED, CONTROLLED STUDY OF RESTORATION OF PIGMENT IN HYPOPIGMENTED BURN SCARS · CONTINUED POSITIVE DATA FROM REPIGMENTATION TRIALS TO FORM BASIS FOR PIII PIVOTAL IDE SUBMISSION WITH US FDA NORTHRIDGE, Calif., and CAMBRIDGE, United Kingdom, 18 October 2013– Regenerative medicine Company Avita Medical Ltd. (ASX: AVH), (OTCQX:AVMXY) is […]
Saluda Medical – Aussie innovation gives hope to back pain sufferers
/in Portfolio Companies, Saluda MedicalOctober 14, 2015: 9NEWS spoke exclusively to the first patient to undergo the new treatment that is giving hope to sufferers of back pain. Read more at http://www.9news.com.au/national/2015/10/14/19/04/aussie-innovation-gives-hope-to-back-pain-sufferers#b0dfx4DwJTTVgPDM.99
Saluda spinal implant for pain relief heralded as ‘breakthrough’
/in Portfolio Companies, Saluda MedicalHarriet Alexander Sydney Morning Herald. Published: October 14, 2015 6:34PM Every minute of the night and day, for decades, Jaswir Grewal was in pain. The constant ache in his back forced him to leave his jobs as a mechanic and banana grower. The pain troubled his sleep, made him irritable with his wife, depressed about his […]
Avita Medical Gains CE Mark for ReGenerCell® and ReNovaCell® to Complete Skin Healing Portfolio Certification Applies to ReCell®, ReGenerCell® and ReNovaCell®
/in Avita Medical, Portfolio CompaniesNorthridge, CA and Cambridge, United Kingdom, 7 October 2015 Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for […]
Avita Medical CEO Adam Kelliher interviewed on CommSec
/in Avita Medical, Portfolio CompaniesLink here.
Avita Medical Announces U.S. FDA Doubles Patient Numbers Permitted for Compassionate Use of ReCell®
/in Avita Medical, Portfolio CompaniesNorthridge, CA and Cambridge, United Kingdom, 5 October 2015 Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced approval from the U.S. Food and Drug Administration (FDA) for the expansion of its Compassionate Use Investigational Device Exemption (IDE) program for ReCell®. The IDE […]
SeaDragon raises $10.009 million
/in Portfolio Companies, SeaDragonSEA: NZX and Media Release 30 September 2015. NZX link here. SeaDragon raises $10.009 million via rights offer and shortfall bookbuild, and additional placement Successful capital raising at $0.008 per share facilitates the completion of the company’s new Omega-3 fish oil refinery. New Zealand’s leading refiner and blender of high-quality fish oils SeaDragon Limited (NZX:SEA) today […]